To further confirm our hypothesis that TG2 promotes BC cell proliferation by activation of the MEK/ERK/LDH pathway and reprogramming of cell metabolism, the MEK inhibitor U0126 was used to perform rescue experiments. Here, MAP2K7 is linked to breast cancer.